[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2176232T3 - Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter. - Google Patents

Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.

Info

Publication number
ES2176232T3
ES2176232T3 ES94900794T ES94900794T ES2176232T3 ES 2176232 T3 ES2176232 T3 ES 2176232T3 ES 94900794 T ES94900794 T ES 94900794T ES 94900794 T ES94900794 T ES 94900794T ES 2176232 T3 ES2176232 T3 ES 2176232T3
Authority
ES
Spain
Prior art keywords
helicobacter
infection
prevention
treatment
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94900794T
Other languages
English (en)
Inventor
Pierre Michetti
Andre Blum
Catherine Davin
Rainer Haas
Irene Corthesy-Theulaz
Jean-Pierre Kraehenbuhl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Biologics LLC
Original Assignee
OraVax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25517797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2176232(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by OraVax Inc filed Critical OraVax Inc
Application granted granted Critical
Publication of ES2176232T3 publication Critical patent/ES2176232T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO DE OBTENER EN UN MAMIFERO ANFITRION UNA RESPUESTA INMUNE DE PROTECCION PARA INFECCION DE HELICOBACTER POR ADMINISTRACION AL ANFITRION DE UNA CANTIDAD INMUNOGENICAMENTE EFECTIVA DE UNA UREASA O SUBUNIDADES DE UREASA DE HELICOBACTER COMO ANTIGENO. TAMBIEN SE PROPORCIONAN COMPOSICIONES DE VACUNA.
ES94900794T 1992-11-03 1993-11-02 Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter. Expired - Lifetime ES2176232T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97099692A 1992-11-03 1992-11-03
US08/085,938 US5972336A (en) 1992-11-03 1993-07-06 Urease-based vaccine against helicobacter infection

Publications (1)

Publication Number Publication Date
ES2176232T3 true ES2176232T3 (es) 2002-12-01

Family

ID=25517797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94900794T Expired - Lifetime ES2176232T3 (es) 1992-11-03 1993-11-02 Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.

Country Status (29)

Country Link
US (1) US5972336A (es)
EP (2) EP1170016A3 (es)
JP (1) JPH07503255A (es)
KR (1) KR100287424B1 (es)
CN (1) CN1111429C (es)
AT (1) ATE217196T1 (es)
AU (2) AU678195C (es)
BR (1) BR9305711A (es)
CA (1) CA2127283A1 (es)
CZ (1) CZ284416B6 (es)
DE (1) DE69331901T2 (es)
DK (1) DK0625053T3 (es)
ES (1) ES2176232T3 (es)
FI (1) FI112032B (es)
GE (1) GEP20012429B (es)
HU (1) HU219760B (es)
IL (1) IL107474A (es)
MX (1) MX9306841A (es)
NO (1) NO942490L (es)
NZ (2) NZ299149A (es)
OA (1) OA10087A (es)
PL (1) PL174448B1 (es)
PT (1) PT625053E (es)
RO (1) RO114870B1 (es)
RU (1) RU2125891C1 (es)
SG (1) SG70978A1 (es)
SK (1) SK280619B6 (es)
WO (1) WO1994009823A1 (es)
ZA (1) ZA938203B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
WO1995014093A1 (en) 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
CA2154063C (en) * 1993-07-27 2006-11-21 Christopher Vincent Doidge Treatment of h. pylori associated gastroduodenal disease
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
AUPM612494A0 (en) 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
AU702878B2 (en) * 1994-06-08 1999-03-11 Csl Limited Treatment and prevention of helicobacter infection
JPH10502365A (ja) * 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
ATE433325T1 (de) * 1995-04-28 2009-06-15 Merieux Oravax Snc Multimerer, rekombinanter urease impfstoff
WO1997005267A2 (en) * 1995-07-26 1997-02-13 Maxim Pharmaceuticals Mucosal delivery of polynucleotides
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
AU7537598A (en) * 1997-04-30 1998-11-24 Pasteur Merieux Serums Et Vaccins Dna based anti-(helicobacter) vaccine composition
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US5985631A (en) 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
EP1105159A2 (en) 1998-06-19 2001-06-13 Mérieux Oravax Lt and ct in parenteral immunization methods against helicobacter infection
US6190667B1 (en) 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
WO2000003730A1 (en) * 1998-07-16 2000-01-27 Cheil Jedang Corporation Urease based vaccine against helicobacter infection
DK1146906T3 (da) * 1999-02-05 2011-10-24 Alk Abello As Mukosalt afgivelsessystem
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
DK2116257T3 (da) 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
AUPR524101A0 (en) * 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
ATE451386T1 (de) * 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN100460014C (zh) * 2006-07-20 2009-02-11 中国人民解放军第三军医大学 基于尿素酶b亚单位活性片段的幽门螺杆菌疫苗及其制备方法
CN101611143B (zh) * 2006-11-10 2015-01-14 翁德克控股有限公司 将肽递送入胃粘膜的方法和装置
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR100982489B1 (ko) * 2007-12-17 2010-09-15 대구한의대학교산학협력단 헬리코박터 파일로리로부터 유래된 항원을 이용하여헬리코박터 파일로리 특이 항체 생산을 위한 백신을제조하는 방법
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2837939A1 (en) * 2013-08-13 2015-02-18 Technische Universität München Method for the detection of H.pylori infection
SG11201603487YA (en) 2013-11-04 2016-05-30 Uti Limited Partnership Methods and compositions for sustained immunotherapy
AU2016275312B2 (en) 2015-05-06 2021-12-23 Uti Limited Partnership Nanoparticle compositions for sustained therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JPH04169539A (ja) * 1990-11-01 1992-06-17 Imuno Japan:Kk 消化器疾患治療・予防剤およびその製造方法
CA2109088A1 (en) * 1991-04-26 1992-10-27 Emanuel Calenoff Methods to detect and treat diseases caused by bacterial allergens
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US5859219A (en) * 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
DE69333110T2 (de) * 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US5681736A (en) * 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine

Also Published As

Publication number Publication date
CZ284416B6 (cs) 1998-11-11
RO114870B1 (ro) 1999-08-30
DK0625053T3 (da) 2002-08-12
PL174448B1 (pl) 1998-07-31
SK280619B6 (sk) 2000-05-16
NO942490D0 (no) 1994-07-01
AU678195B2 (en) 1997-05-22
KR100287424B1 (ko) 2001-04-16
SG70978A1 (en) 2000-03-21
HU219760B (hu) 2001-07-30
WO1994009823A1 (en) 1994-05-11
EP0625053A1 (en) 1994-11-23
US5972336A (en) 1999-10-26
NO942490L (no) 1994-08-22
DE69331901T2 (de) 2002-10-31
DE69331901D1 (de) 2002-06-13
AU2003270987A1 (en) 2004-01-22
EP1170016A2 (en) 2002-01-09
IL107474A0 (en) 1994-02-27
AU678195C (en) 2003-06-12
PL304419A1 (en) 1995-01-09
OA10087A (en) 1996-12-18
CN1111429C (zh) 2003-06-18
MX9306841A (es) 1995-01-31
CA2127283A1 (en) 1994-05-11
CZ160994A3 (en) 1995-04-12
IL107474A (en) 1998-09-24
EP1170016A3 (en) 2002-03-06
HUT69938A (en) 1995-09-28
FI943171A (fi) 1994-09-01
JPH07503255A (ja) 1995-04-06
RU2125891C1 (ru) 1999-02-10
SK79394A3 (en) 1996-09-04
HU9402261D0 (en) 1994-10-28
FI943171A0 (fi) 1994-07-01
NZ258118A (en) 1997-04-24
ZA938203B (en) 1994-06-09
NZ299149A (en) 1997-12-19
BR9305711A (pt) 1997-02-18
PT625053E (pt) 2002-09-30
EP0625053B1 (en) 2002-05-08
ATE217196T1 (de) 2002-05-15
GEP20012429B (en) 2001-05-25
AU5561994A (en) 1994-05-24
CN1094640A (zh) 1994-11-09
FI112032B (fi) 2003-10-31

Similar Documents

Publication Publication Date Title
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
ES2092306T3 (es) Adyuvante para vacunas.
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
LV10203A (lv) Panemiens inficesanas ar AIDS noteiksanai olbaltumvielu kompozicija test-komplekts
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
ES2149776T3 (es) Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
YU28392A (sh) Vakcina koja sadrži glikoprotein d i 3deacilovani monofosforil lipid a
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
NL300185I1 (nl) Acellulair vaccin.
PT833903E (pt) Vacina multivalente de coroanavirus de bovino e metodo para tratar a infeccao decoronavirus de bovino
EP0048422A3 (en) Pili of pseudomonas aeruginosa and utilization of same as vaccines against infectionary p.aeruginosa
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
ES515472A0 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
IT8121484A0 (it) Estratto da piante del genere epimedium, procedimento per lapreparazione di detto estratto, agente immunostimolante che comprende detto estratto come componente efficace e immunoterapia mediante l'impiego di detto estratto.
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
SU1565027A1 (ru) Инактиватор вируса западного нила